916
Participants
Start Date
April 30, 2012
Primary Completion Date
March 31, 2014
Study Completion Date
March 31, 2014
Fasiglifam (TAK-875)
Fasiglifam (TAK-875) tablets
Sitagliptin
Sitagliptin tablets
Placebo
Placebo-matching tablets
Muscle Shoals
Mesa
Peoria
Phoenix
Chula Vista
El Cajon
La Mesa
Laguna Hills
National City
Paramount
San Diego
Stockton
Tustin
West Hills
Trumbull
Coral Gables
Jacksonville
Miami
New Port Richey
Ocala
West Palm Beach
Meridian
Chicago
Greenfield
Muncie
Lexington
Owensboro
Hyattsville
Troy
Picayune
St Louis
Haddon Heights
Rosedale
Calabash
Charlotte
Monroe
Morehead City
Winston-Salem
Cincinnati
Cleveland
Dayton
Norman
Lancaster
Levittown
Spartanburg
Crossville
Memphis
Carrollton
Houston
Irving
Katy
McKinney
Plano
San Antonio
Spring
Salt Lake City
West Jordan
Richmond
Camperdown
Maroubra
Redcliffe
Adelaide
Daw Park
Box Hill
Fitzroy
Melbourne
Byala
Kazanlak
Plovdiv
Sofia
Čakovec
Karlovac
Krapinske Toplice
Rijeka
Slavonski Brod
Split
Zadar
Zagreb
Beroun
Brno
Havlíčkův Brod
Kladno
Kroměříž
Mladá Boleslav
Ostrava
Ostrava - Moravska Ostrava
Pardubice
Pilsen
Písek
Prague
Ústí nad Labem
Baja
Balatonfüred
Budaörs
Budapest
Debrecen
Eger
Gödöllő
Gyöngyös
Gyula
Hódmezővásárhely
Kecskemét
Kistelek
Kisvárda
Komárom
Mohács
Nyíregyháza
Pécs
Szeged
Szekszárd
Szikszó
Szolnok
Szombathely
Úrhida
Veszprém
Zalaegerszeg
Florence
Milan
Sesto San Giovanni
Pavia
Johor Bahru
Alor Star
Kelantan
Kota Bharu
Cheras
Kuala Lumpur
Lembah Pantai
Petaling Jaya
Banská Bystrica
Bardejov
Bratislava
Kosice - Saca
Košice
Levice
Lučenec
Moldava nad Bodvou
Nitra
Pezinok
Prešov
Prievidza
Stropkov
Svidník
Šahy
Štúrovo
Trebišov
Trenčín
Žilina
Goyang-si
Seongnam-si
Incheon
Seoul
Bangkok
Patumwan
Rachathevi
Rajtevi
Ratchathewi
Khon Kaen
Muang
Hat Yai
Muang
Lead Sponsor
Takeda
INDUSTRY